Developer docs
API playgroundTry for free, no card

Search company profiles

Inibsa

Full company profile

uuid000g74r

Namestring
Inibsa
Legal namestring
Laboratorios Inibsa S.A.
Websiteurl
inibsa.com
Company typeenum
Private
Founded yearint
1948
Descriptiontext

Inibsa (Laboratorios Inibsa S.A.) is a privately held Spanish pharmaceutical company founded in 1948 by Dr. Pedro Junyent in Barcelona, specializing in the development, manufacture, and global distribution of dental anaesthetic products and pain control solutions for dental professionals. The company's core portfolio comprises injectable anaesthetics (Articaine, Lidocaine, Mepivacaine, and Bupivacaine formulations marketed under the Artinibsa, Xilonibsa, Scandinibsa, and Inibsacain brands), topical anaesthetics (Xilonibsa spray 10%), sterile single-use dental needles (MONOPROTECT and MONOPROTECT PLUS lines), and reusable dental cartridge syringes (Prestoject CW, HK, FL, IL, and Safety Stand models). Inibsa is positioned as the world's second-largest producer of dental anaesthesia and serves dental professionals in more than 60 countries through a combination of wholly-owned subsidiaries and distributor networks.

The company operates an 18,000 m² manufacturing and innovation facility in Lliçà de Vall (Barcelona), equipped with optical inspection systems for cartridge quality control, two aseptic filling areas housed in grade B cleanroom environments, and proprietary microbiology (opened 2016), physicochemical (opened 2017), and materials laboratories. Inibsa produces over 1 million dental anaesthetic cartridges per day and holds 100+ pharmaceutical dossiers registered globally. The facility is inspected and approved by major regulatory agencies including AEMPS (Spain), CFDA (China), PPB (Kenya), and the Russian Ministry of Health. Between 2020 and 2022, the entire production plant underwent full renovation and expansion, including two new aseptic fill areas, a transition to RABS (Restricted Access Barrier System), and renewed packaging lines.

Inibsa generates revenue through B2B sales of pharmaceutical and medical-device products to dental professionals via a dual-channel distribution model: wholly-owned subsidiaries in Portugal (since 1960) and Russia (since 2020), plus a network of leading distributors across 50+ additional countries covering Europe, the Middle East, Africa, Asia-Pacific, and the Americas. The company employs more than 375 people, remains privately held with no disclosed parent company or institutional investors, and pursues marketing through clinical educational content (blog), social media (Facebook, Instagram, LinkedIn), and industry conference participation (e.g., AEEDC). Pricing is not publicly disclosed and is handled through distributor and subsidiary relationships.

Short descriptiontext

Inibsa is a Spain-based pharmaceutical manufacturer specializing in dental anaesthetics (injectable and topical), dental needles, and syringes. The company serves dental professionals across 60+ countries via direct subsidiaries and distributor networks, and is the world's second-largest producer of dental anaesthesia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLlissá De Vall, Spain
HQ citystring
Llissá De Vall
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dental anaesthetics manufacturing, pharmaceutical dental products, dental needles syringes, local anaesthetic cartridges, pain control dentistry
NAICS code2 codes
  • Dental Equipment and Supplies Manufacturing339114
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Dental Anaesthesia Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Medical Device Sales
TypeHardware Sales
Description

Revenue generated from manufacturing and selling dental anaesthetics (injectable and topical), dental needles, and dental syringes to dental professionals worldwide through subsidiaries and distributor networks.

inibsa.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1B2B pharmaceutical products - pricing available through distributor inquiries
ModelOtherBilling cadenceOther
Notes

Products are sold to dental professionals through distributor networks. Pricing not publicly disclosed on the company website.

inibsa.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Artinibsa
Description

Articaine-based injectable dental anaesthetic brand (4% with epinephrine 1:100,000 or 1:200,000)

inibsa.com
+5 more records
Core offering1 text field

Laboratorios Inibsa S.A. manufactures and sells a full dental pain-control portfolio: injectable local anaesthetics (Articaine, Lidocaine, Mepivacaine and Bupivacaine formulations), topical anaesthetics (Lidocaine 10% spray), sterile single-use dental needles, and reusable stainless-steel dental cartridge syringes. The products are sold under Inibsa-owned brands (Artinibsa, Xilonibsa, Scandinibsa, Inibsacain, MONOPROTECT, Prestoject) to dental professionals globally through direct subsidiaries and distributor networks in more than 60 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Products available in more than 60 countries
+2 more records
Product overview1 text field

Inibsa is a Spain-based manufacturer of dental anaesthetic products and pain control solutions. The company operates as a single unified product portfolio organized into four main categories: Injectable Anaesthetics (Artinibsa, Xilonibsa, Scandinibsa, and Inibsacain product lines with various concentrations and vasoconstrictor options), Topical Anaesthetics (Xilonibsa spray 10%), Dental Needles (MONOPROTECT® INIBSA and MONOPROTECT® Inibsa PLUS), and Dental Syringes (Prestoject® series including CW, HK, FL, IL models and Safety stand accessory). These products form a comprehensive pain control ecosystem designed for dental professionals, supporting procedures from routine cleanings to complex surgical interventions.

Product and service9 records
1Artinibsa Injectable Anaesthetics (Articaine 4% with epinephrine)
CategoryInjectable Anaesthetic
Description

Articaine-based injectable dental anaesthetic with epinephrine (1:100,000 and 1:200,000 variants) for prolonged and medium-duration dental procedures, providing 45–75 minutes of pulpal anaesthesia and extended soft-tissue anaesthesia. Designed for dental professionals performing restorative and surgical procedures.

2Xilonibsa 2% Injectable Anaesthetic (Lidocaine with epinephrine)
CategoryInjectable Anaesthetic
Description

Lidocaine-based injectable dental anaesthetic (2% with epinephrine 1:80,000), positioned as the gold standard for versatile dental anaesthesia, offering approximately 60 minutes of pulpal anaesthesia and 180 minutes of soft-tissue anaesthesia. Designed for general dental practitioners performing routine procedures.

3Scandinibsa Injectable Anaesthetics (Mepivacaine 2% and 3%)
CategoryInjectable Anaesthetic
Description

Mepivacaine-based injectable dental anaesthetics available in 3% plain (without vasoconstrictor, for patients where vasoconstrictors are contraindicated) and 2% with epinephrine 1:100,000 formulations, offering short-to-medium pulpal anaesthesia duration suitable for special situations and surgical procedures.

4Inibsacain 0.5% Injectable Anaesthetic (Bupivacaine)
CategoryInjectable Anaesthetic
Description

Bupivacaine-based long-acting injectable dental anaesthetic (0.5% with epinephrine 1:200,000) for postoperative pain control, providing up to 12 hours of effect and 90–180 minutes of pulpal anaesthesia. Designed for dental practitioners managing post-surgical and complex procedure pain.

5Xilonibsa Spray 10% Topical Anaesthetic
CategoryTopical Anaesthetic
Description

Lidocaine 10% topical anaesthetic spray for intraoral surface anaesthesia prior to injection, providing 1–3 minutes of onset and approximately 15 minutes of duration with a banana flavour. Designed for dental professionals to minimise injection discomfort.

6MONOPROTECT INIBSA Sterile Single-Use Dental Needles
CategoryDental Needle
Description

Sterile single-use dental needles with stainless-steel cannulas, silicon-coated tip and triple-bevel design for smooth and precise injections. Available in multiple gauges (27G–30G) and lengths (12mm–36mm). Designed for dental professionals performing routine injectable anaesthesia.

7MONOPROTECT Inibsa PLUS Dental Needles
CategoryDental Needle
Description

Enhanced sterile single-use dental needles with a 43% wider inner diameter for smoother flow of anaesthetic solution, lower injection pressure and easier aspiration technique. Designed for dental practitioners seeking premium flow performance in injectable anaesthesia.

8Prestoject Dental Syringes (CW, HK, FL, IL models)
CategoryDental Syringe
Description

Stainless-steel reusable dental cartridge syringes for 1.8 mL dental cartridges, with ergonomic designs for secure, comfortable grip and high resistance to cleaning agents, suitable for thermal disinfection and 134°C sterilisation. Models include CW (Crawford-tip aspirating), HK (three-hook aspirating), FL (self-aspirating flat-tip) and IL (intraligamental with anti-bursting sleeve). Designed for dental professionals performing injectable anaesthesia across different clinical techniques.

9Prestoject Safety Stand
CategoryDental Syringe Accessory
Description

Needle recapping device and syringe holder made of heavy stainless steel with mechanical locking, designed to prevent needle-stick injuries during dental treatment. Aimed at dental practitioners seeking enhanced safety accessories for their injection workflow.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Social responsibility partnership involving participation in Magic Line 2024 with a donation of 5000 euros to support hospital activities.

2Fundació Somni dels Nens
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Collaboration to help children with cancer or chronic illnesses through charitable activities.

inibsa.com
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Sponsorship supporting patients with hereditary conditions resulting in gastrointestinal tumors.

Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Financial collaboration by Inibsa employees to support individuals at risk of food insecurity.

5ROV DENTAL (Madagascar)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Local distributor in Madagascar for donation of products for charitable dental activities.

inibsa.com
6Fundo iMM-Laço (Portugal)
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Donation to fight breast cancer through their local Portugal subsidiary.

inibsa.com
7AMPBD - Association Marocaine de Prévention Bucco-Dentaire
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Collaboration through local distributor Hemolab to promote oral hygiene and access to oral health in Morocco.

inibsa.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Global #1 in dental anesthetics headquartered in France. Septodont is the most direct competitor to Inibsa — both manufacture injectable dental anesthetics (articaine, lidocaine, mepivacaine) and sell globally to dental professionals, competing head-to-head on the same product category and customer base.

TypeDirect peer
Description

Italy-based pharmaceutical manufacturer specializing in dental anesthetics and related products. Pierrel competes directly with Inibsa in dental injectable anesthetics and serves overlapping European and international dental professional markets.

TypeDirect peer
Description

Colombian manufacturer of dental anesthetics and consumables with strong Latin American presence. New Stetic is a direct competitor in the dental injectable anesthetic category and overlaps with Inibsa in cartridge-based local anesthetics.

TypeBroad incumbent
Description

Largest dental equipment and consumables manufacturer globally, publicly listed. Dentsply Sirona offers endodontic, restorative, and a broader dental consumables portfolio that overlaps with Inibsa's needles and syringes categories, though it is not focused on injectable anesthetics.

TypeBroad incumbent
Description

Largest dental distributor globally and a major force in dental practice supplies. Henry Schein serves the same dental professional customer base as Inibsa and competes indirectly as a platform that aggregates competing anesthetic brands for sale to practitioners.

TypeEmerging player
Description

US-based manufacturer of dental materials including anesthetics, hemostatic agents, and restorative products. Ultradent overlaps with Inibsa in topical and injectable dental anesthetics, with partial overlap in needles/syringes via consumable accessories.

TypeEmerging player
Description

Swiss dental manufacturer focused on endodontics, restorative materials, and rotary instruments. Coltene is comparable as a mid-sized specialty dental manufacturer selling consumables to dental professionals, with overlap in needle/syringe-adjacent categories.

TypeEmerging player
Description

German dental materials manufacturer specializing in restoratives, preventive care, and digital dentistry workflows. DMG is comparable as a privately held, mid-sized European dental specialty manufacturer serving the same dental professional customer base.

TypeBroad incumbent
Description

Large global healthcare conglomerate with a meaningful dental and oral care business. 3M competes adjacent to Inibsa in dental restoratives, preventive products, and certain dental supplies sold to the same professional customer base.

TypeRegional player
Description

Indian dental pharmaceutical manufacturer specializing in local anesthetics and dental products. ICPA is comparable as a regional dental anesthetic manufacturer serving South Asian and emerging markets, overlapping with Inibsa in injectable dental anesthetics but in different geographies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inibsa

Dental Anaesthesia Manufacturinginibsa.com

Inibsa is a Spain-based pharmaceutical manufacturer specializing in dental anaesthetics (injectable and topical), dental needles, and syringes. The company serves dental professionals across 60+ countries via direct subsidiaries and distributor networks, and is the world's second-largest producer of dental anaesthesia.

What Inibsa does

Inibsa (Laboratorios Inibsa S.A.) is a privately held Spanish pharmaceutical company founded in 1948 by Dr. Pedro Junyent in Barcelona, specializing in the development, manufacture, and global distribution of dental anaesthetic products and pain control solutions for dental professionals. The company's core portfolio comprises injectable anaesthetics (Articaine, Lidocaine, Mepivacaine, and Bupivacaine formulations marketed under the Artinibsa, Xilonibsa, Scandinibsa, and Inibsacain brands), topical anaesthetics (Xilonibsa spray 10%), sterile single-use dental needles (MONOPROTECT and MONOPROTECT PLUS lines), and reusable dental cartridge syringes (Prestoject CW, HK, FL, IL, and Safety Stand models). Inibsa is positioned as the world's second-largest producer of dental anaesthesia and serves dental professionals in more than 60 countries through a combination of wholly-owned subsidiaries and distributor networks.

The company operates an 18,000 m² manufacturing and innovation facility in Lliçà de Vall (Barcelona), equipped with optical inspection systems for cartridge quality control, two aseptic filling areas housed in grade B cleanroom environments, and proprietary microbiology (opened 2016), physicochemical (opened 2017), and materials laboratories. Inibsa produces over 1 million dental anaesthetic cartridges per day and holds 100+ pharmaceutical dossiers registered globally. The facility is inspected and approved by major regulatory agencies including AEMPS (Spain), CFDA (China), PPB (Kenya), and the Russian Ministry of Health. Between 2020 and 2022, the entire production plant underwent full renovation and expansion, including two new aseptic fill areas, a transition to RABS (Restricted Access Barrier System), and renewed packaging lines.

Inibsa generates revenue through B2B sales of pharmaceutical and medical-device products to dental professionals via a dual-channel distribution model: wholly-owned subsidiaries in Portugal (since 1960) and Russia (since 2020), plus a network of leading distributors across 50+ additional countries covering Europe, the Middle East, Africa, Asia-Pacific, and the Americas. The company employs more than 375 people, remains privately held with no disclosed parent company or institutional investors, and pursues marketing through clinical educational content (blog), social media (Facebook, Instagram, LinkedIn), and industry conference participation (e.g., AEEDC). Pricing is not publicly disclosed and is handled through distributor and subsidiary relationships.

Inibsa firmographics

Firmographics
Name
Inibsa
Legal name
Laboratorios Inibsa S.A.
Website
https://inibsa.com
Company type
Private
Founded year
1948
Operating status
Operating
Headcount range
251–500 employees
Short description
Inibsa is a Spain-based pharmaceutical manufacturer specializing in dental anaesthetics (injectable and topical), dental needles, and syringes. The company serves dental professionals across 60+ countries via direct subsidiaries and distributor networks, and is the world's second-largest producer of dental anaesthesia.
Ownership category
akta.pro rank

Where Inibsa is headquartered

Location

Headquarters

HQ city
Llissá De Vall
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

Inibsa business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical/Medical Device Sales: Revenue generated from manufacturing and selling dental anaesthetics (injectable and topical), dental needles, and dental syringes to dental professionals worldwide through subsidiaries and distributor networks.

Pricing tiers

ModelBillingPrice
OtherOtherB2B pharmaceutical products - pricing available through distributor inquiries

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Inibsa product offering

Product offering

Core offering

Laboratorios Inibsa S.A. manufactures and sells a full dental pain-control portfolio: injectable local anaesthetics (Articaine, Lidocaine, Mepivacaine and Bupivacaine formulations), topical anaesthetics (Lidocaine 10% spray), sterile single-use dental needles, and reusable stainless-steel dental cartridge syringes. The products are sold under Inibsa-owned brands (Artinibsa, Xilonibsa, Scandinibsa, Inibsacain, MONOPROTECT, Prestoject) to dental professionals globally through direct subsidiaries and distributor networks in more than 60 countries.

Product overview

Inibsa is a Spain-based manufacturer of dental anaesthetic products and pain control solutions. The company operates as a single unified product portfolio organized into four main categories: Injectable Anaesthetics (Artinibsa, Xilonibsa, Scandinibsa, and Inibsacain product lines with various concentrations and vasoconstrictor options), Topical Anaesthetics (Xilonibsa spray 10%), Dental Needles (MONOPROTECT® INIBSA and MONOPROTECT® Inibsa PLUS), and Dental Syringes (Prestoject® series including CW, HK, FL, IL models and Safety stand accessory). These products form a comprehensive pain control ecosystem designed for dental professionals, supporting procedures from routine cleanings to complex surgical interventions.

Differentiator

Problem solved

Functional benefit

Brands

  • Artinibsa: Articaine-based injectable dental anaesthetic brand (4% with epinephrine 1:100,000 or 1:200,000)
  • Xilonibsa
  • Scandinibsa
  • Inibsacain
  • MONOPROTECT
  • Prestoject

Products and services

  • Artinibsa Injectable Anaesthetics (Articaine 4% with epinephrine) Articaine-based injectable dental anaesthetic with epinephrine (1:100,000 and 1:200,000 variants) for prolonged and medium-duration dental procedures, providing 45–75 minutes of pulpal anaesthesia and extended soft-tissue anaesthesia. Designed for dental professionals performing restorative and surgical procedures.
  • Xilonibsa 2% Injectable Anaesthetic (Lidocaine with epinephrine) Lidocaine-based injectable dental anaesthetic (2% with epinephrine 1:80,000), positioned as the gold standard for versatile dental anaesthesia, offering approximately 60 minutes of pulpal anaesthesia and 180 minutes of soft-tissue anaesthesia. Designed for general dental practitioners performing routine procedures.
  • Scandinibsa Injectable Anaesthetics (Mepivacaine 2% and 3%) Mepivacaine-based injectable dental anaesthetics available in 3% plain (without vasoconstrictor, for patients where vasoconstrictors are contraindicated) and 2% with epinephrine 1:100,000 formulations, offering short-to-medium pulpal anaesthesia duration suitable for special situations and surgical procedures.
  • Inibsacain 0.5% Injectable Anaesthetic (Bupivacaine) Bupivacaine-based long-acting injectable dental anaesthetic (0.5% with epinephrine 1:200,000) for postoperative pain control, providing up to 12 hours of effect and 90–180 minutes of pulpal anaesthesia. Designed for dental practitioners managing post-surgical and complex procedure pain.
  • Xilonibsa Spray 10% Topical Anaesthetic Lidocaine 10% topical anaesthetic spray for intraoral surface anaesthesia prior to injection, providing 1–3 minutes of onset and approximately 15 minutes of duration with a banana flavour. Designed for dental professionals to minimise injection discomfort.
  • MONOPROTECT INIBSA Sterile Single-Use Dental Needles Sterile single-use dental needles with stainless-steel cannulas, silicon-coated tip and triple-bevel design for smooth and precise injections. Available in multiple gauges (27G–30G) and lengths (12mm–36mm). Designed for dental professionals performing routine injectable anaesthesia.
  • MONOPROTECT Inibsa PLUS Dental Needles Enhanced sterile single-use dental needles with a 43% wider inner diameter for smoother flow of anaesthetic solution, lower injection pressure and easier aspiration technique. Designed for dental practitioners seeking premium flow performance in injectable anaesthesia.
  • Prestoject Dental Syringes (CW, HK, FL, IL models) Stainless-steel reusable dental cartridge syringes for 1.8 mL dental cartridges, with ergonomic designs for secure, comfortable grip and high resistance to cleaning agents, suitable for thermal disinfection and 134°C sterilisation. Models include CW (Crawford-tip aspirating), HK (three-hook aspirating), FL (self-aspirating flat-tip) and IL (intraligamental with anti-bursting sleeve). Designed for dental professionals performing injectable anaesthesia across different clinical techniques.
  • Prestoject Safety Stand Needle recapping device and syringe holder made of heavy stainless steel with mechanical locking, designed to prevent needle-stick injuries during dental treatment. Aimed at dental practitioners seeking enhanced safety accessories for their injection workflow.

Quantifiable outcome

  • Products available in more than 60 countries
  • +2 more outcomes

Companies that use Inibsa

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Inibsa technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Inibsa partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor.

  • Hospital Sant Joan de Déu BarcelonaminorOthers · 1 January 2024Social responsibility partnership involving participation in Magic Line 2024 with a donation of 5000 euros to support hospital activities.
  • Fundació Somni dels NensminorOthers · 1 January 2024Collaboration to help children with cancer or chronic illnesses through charitable activities.
  • IDIBELL (Fundació Institut d'Investigació Biomèdica de Bellvitge)minorOthers · 1 January 2024Sponsorship supporting patients with hereditary conditions resulting in gastrointestinal tumors.
  • Fundació Banc dels AlimentsminorOthers · 1 January 2024Financial collaboration by Inibsa employees to support individuals at risk of food insecurity.
  • ROV DENTAL (Madagascar)minorChannel Partner/ Reseller/ Distributor · 1 January 2024Local distributor in Madagascar for donation of products for charitable dental activities.
  • Fundo iMM-Laço (Portugal)minorOthers · 1 January 2024Donation to fight breast cancer through their local Portugal subsidiary.
  • AMPBD - Association Marocaine de Prévention Bucco-DentaireminorOthers · 1 January 2024Collaboration through local distributor Hemolab to promote oral hygiene and access to oral health in Morocco.

Scale indicators7 records

Recent moves4 records

Inibsa competitors and assessment

Company assessment

Direct peers

  • Septodont: Global #1 in dental anesthetics headquartered in France. Septodont is the most direct competitor to Inibsa — both manufacture injectable dental anesthetics (articaine, lidocaine, mepivacaine) and sell globally to dental professionals, competing head-to-head on the same product category and customer base.
  • Pierrel: Italy-based pharmaceutical manufacturer specializing in dental anesthetics and related products. Pierrel competes directly with Inibsa in dental injectable anesthetics and serves overlapping European and international dental professional markets.
  • New Stetic: Colombian manufacturer of dental anesthetics and consumables with strong Latin American presence. New Stetic is a direct competitor in the dental injectable anesthetic category and overlaps with Inibsa in cartridge-based local anesthetics.

Broad incumbents

  • Dentsply Sirona: Largest dental equipment and consumables manufacturer globally, publicly listed. Dentsply Sirona offers endodontic, restorative, and a broader dental consumables portfolio that overlaps with Inibsa's needles and syringes categories, though it is not focused on injectable anesthetics.
  • Henry Schein: Largest dental distributor globally and a major force in dental practice supplies. Henry Schein serves the same dental professional customer base as Inibsa and competes indirectly as a platform that aggregates competing anesthetic brands for sale to practitioners.
  • 3M Oral Care Solutions: Large global healthcare conglomerate with a meaningful dental and oral care business. 3M competes adjacent to Inibsa in dental restoratives, preventive products, and certain dental supplies sold to the same professional customer base.

Emerging players

  • Ultradent Products: US-based manufacturer of dental materials including anesthetics, hemostatic agents, and restorative products. Ultradent overlaps with Inibsa in topical and injectable dental anesthetics, with partial overlap in needles/syringes via consumable accessories.
  • Coltène/Whaledent: Swiss dental manufacturer focused on endodontics, restorative materials, and rotary instruments. Coltene is comparable as a mid-sized specialty dental manufacturer selling consumables to dental professionals, with overlap in needle/syringe-adjacent categories.
  • DMG Dental (Dental Manufacturing Group): German dental materials manufacturer specializing in restoratives, preventive care, and digital dentistry workflows. DMG is comparable as a privately held, mid-sized European dental specialty manufacturer serving the same dental professional customer base.

Regional players

Market position

Strengths4 records

Weaknesses4 records

Key risks5 records

Key highlights7 records

Customer concentration

Inibsa social profiles

Digital presence

Inibsa compliance and trust

Trust signal

Compliance4 records

Inibsa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inibsa leadership team

Management profile

Number of profiles

Profiles14 records

Inibsa subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Inibsa funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inibsa M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inibsa

What does Inibsa do?

Laboratorios Inibsa S.A. manufactures and sells a full dental pain-control portfolio: injectable local anaesthetics (Articaine, Lidocaine, Mepivacaine and Bupivacaine formulations), topical anaesthetics (Lidocaine 10% spray), sterile single-use dental needles, and reusable stainless-steel dental cartridge syringes. The products are sold under Inibsa-owned brands (Artinibsa, Xilonibsa, Scandinibsa, Inibsacain, MONOPROTECT, Prestoject) to dental professionals globally through direct subsidiaries and distributor networks in more than 60 countries.

Is Inibsa a public or private company?

Inibsa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Inibsa founded?

Inibsa was founded in 1948. It employs 251 to 500 people.

Where is Inibsa based?

Inibsa is headquartered in Llissá De Vall, Spain, in the Europe region.

How does Inibsa make money?

One revenue line is on record: pharmaceutical/Medical Device Sales.

Who are Inibsa's main competitors?

Direct peers on record are Septodont, Pierrel and New Stetic. Broad incumbents are Dentsply Sirona, Henry Schein and 3M Oral Care Solutions. Emerging players are Ultradent Products, Coltène/Whaledent and DMG Dental (Dental Manufacturing Group). ICPA Health Products (Indian Health Products & Cosmetics Association member manufacturers) is listed as a regional player.

Does Inibsa have an API?

No public API is recorded for Inibsa.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCompetitive Landscape: Leading Companies and New Entrants in the Dental Syringes MarketThe dental syringes market is projected to reach $4.71 billion by 2030, growing at a compound annual growth rate of 5.7%, driven by technological innovations and increasing demand in outpatient dental facilities. In April 2024, US-based private equity firm Behrman Capital acquired Vista Apex, a medical equipment manufacturer focused on dental syringes, for an undisclosed amount to expand its healthcare portfolio. In May 2024, Spain-based Laboratorios Inibsa introduced its Prestoject dental syringe range featuring ergonomic design and corrosion-resistant stainless steel construction for dental anesthesia applications.GlobeNewswireGlobal Dental Anesthetics Market to Reach USD 1.80 Billion by 2030 | MarketsandMarkets™MarketsandMarkets projects the global dental anesthetics market will grow from US$1.43 billion in 2024 to US$1.80 billion by 2030, driven by a 4.0% CAGR fueled by rising dental infections, an aging population, and advances in Computer-Controlled Local Anesthetic Delivery systems. Major strategic acquisitions are reshaping the competitive landscape, including Septodont Holding's investment in Balanced Pharma (Dec 2024) and its acquisition of Laboratorios Inibsa (Oct 2024), and Pierrel's purchase of 3M's Dental Local Anesthetic portfolio (Aug 2023). Emerging economies in China, India, Mexico, and Brazil represent the highest growth opportunities, with the Asia Pacific region expected to record the strongest CAGR globally.MarketsandMarketsDental Anesthetics Market Report 2025-2030, By Drug Type, Route of Administration, and GeoMarketsandMarkets released a comprehensive report on the global dental anesthetics market, projecting growth from USD 1.48 billion in 2025 to USD 1.80 billion by 2030, representing a CAGR of 4.0%. Key market drivers include rising incidence of dental diseases, increasing demand for cosmetic dental procedures, and growing dental tourism, with Asia Pacific expected to be the fastest-growing region at a CAGR of 4.8%. Recent strategic moves in the sector include Septodont Holding's acquisition of a 51% stake in Laboratorios Inibsa (October 2024) and its strategic investment in Balanced Pharma, Inc. (December 2024), alongside Pierrel's acquisition of 3M's Dental Local Anesthetic portfolio (August 2023).InibsaInibsa group accelerates its development with the support of Septodont and Acteon as new shareholdersInibsa group, a global pharmaceutical group focusing on dental products, has announced that Septodont and Acteon will become shareholders, with Septodont acquiring a controlling stake. This transaction, which is expected to close by the end of the year pending regulatory approvals, represents a significant milestone in Inibsa's growth and will enable further expansion in Iberia and globally. Inibsa's management views the new partnerships as a way to strengthen the company's operational capabilities and market position in dental products.Empresas de Capital Riesgo en EspaBiteRight cierra una ronda de 2.8 M€ liderada por Inibsa y con la participación de Inveready, para su solución de implantología dental de alta precisiónBiteRight secured a €2.8 million Series A funding round led by Inibsa with participation from Inveready to support the commercial expansion of its AI-driven dental implantology platform. The investment, supplemented by non-dilutive financing, will fund growth in Spain and Portugal through an exclusive distribution agreement with Inibsa while continuing research and development efforts.